JANX News & Events

Valuation concerns in the AI capex buildout economy hit the Tech sector - by far the worst performing area of the S&P 500 - particularly hard on Tuesday.  2026 memory and semiconductor highflyers were some of the biggest lowers, as Micronand Sandiskwere the worst performers on the benchmark.  Among the positive areas, the resilient labor market and questions about AI displacement in the human economy have supported Staffing/Employment, as companies like Korn Ferryrallied by over 6% after better than feared results.   Otherwise, the unwind in Tech momentum trade saw sector rotation into the defensive sectors, with Consumer Staples and Healthcare outperforming.In the opening hours of the evening session, equity futures are marginally higher - S&P e-minis are up a decimal and Nasdaq 100 contract is up 0.2%.  In commodities, the perception of progress in the Strait of Hormuz has pressured WTI Crude Oil to low $70s.   Meanwhile the accelerating strength in the U.S. Dollar is weighing deeper on all metals - Gold is below $4,120 and Silver has retreated below $62 per ounce while Copper is at the lowest level since mid-May below $6.15/lb.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER AFTER EARNINGS -Icon plcup 5.1%KB Homeup 3.8%ALSO HIGHER -National Health Investorsup 4.0% after entering S&P SmallCap 600 indexToastup 3.7% after entering S&P MidCap 400 indexIES Holdingsup 3.2% after entering S&P MidCap 400 indexNikeup 1.0% after naming new CFO and affirming guidanceHoneywell Internationalup 0.9% after entering S&P 500 indexAlphabetup 0.7% after entering Dow Jones Industrials AverageDOWN AFTER EARNINGS -Worthingtondown 9.9%Cerebras Systemsdown 10.7%FedExdown 6.3%ALSO LOWER -Janux Therapeuticsdown 3.4% after departure of Chief Medical Officer

In a regulatory filing, Janux Therapeutics disclosed that on June 23, William Go, M.D., Ph.D. departed as Chief Medical Officer of the company under circumstances that the company determined to constitute a termination without "Cause" under the terms of the company's Change in Control and Severance Benefit Plan. "The Company has initiated a search for his successor. In the interim, responsibilities previously overseen by Dr. Go will be assumed by members of the Company's existing clinical leadership team. The transition does not affect the Company's development strategy, regulatory plans, or previously disclosed clinical timelines. Dr. Go's departure was not a result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices," the filing stated.